113 related articles for article (PubMed ID: 8981662)
1. Serum tumour-associated trypsin inhibitor (TATI) and renal function.
Tramonti G; Donadio C; Ferdeghini M; Annichiarico C; Norpoth M; Bianchi R; Bianchi C
Scand J Clin Lab Invest; 1996 Nov; 56(7):653-6. PubMed ID: 8981662
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rate.
Tramonti G; Ferdeghini M; Donadio C; Annichiarico C; Norpoth M; Bianchi R; Bianchi C
Ren Fail; 1998 Mar; 20(2):295-302. PubMed ID: 9574455
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated trypsin inhibitor (TATI) and renal function.
Tramonti G; Ferdeghini M; Donadio C; Annichiarico C; Norpoth M; Bianchi R; Bianchi C
Kidney Int Suppl; 1997 Dec; 63():S179-81. PubMed ID: 9453997
[TBL] [Abstract][Full Text] [Related]
4. Assessment of tumor-associated trypsin inhibitor (TATI) as a marker of renal function.
Tramonti G; Ferdeghini M; Annichiarico C; Donadio C; Norpoth M; Mantuano E; Bianchi C
J Nephrol; 2003; 16(5):663-72. PubMed ID: 14733412
[TBL] [Abstract][Full Text] [Related]
5. Creatinine clearance, cystatin C, beta2-microglobulin and TATI as markers of renal function in patients with proteinuria.
Tramonti G; Cipollini I; Annichiarico C; Lorusso P; Panicucci E; Mariani G; Barsotti G
J Nephrol; 2012; 25(6):976-82. PubMed ID: 22307441
[TBL] [Abstract][Full Text] [Related]
6. Relationship between renal function and blood level of chromogranin A.
Tramonti G; Ferdeghini M; Annichiarico C; Norpoth M; Donadio C; Bianchi R; Bianchi C
Ren Fail; 2001; 23(3-4):449-57. PubMed ID: 11499560
[TBL] [Abstract][Full Text] [Related]
7. Tumour-associated trypsin inhibitor and renal cell carcinoma.
Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
[TBL] [Abstract][Full Text] [Related]
8. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia.
Tramonti G; Ferdeghini M; Donadio C; Norpoth M; Annichiarico C; Bianchi R; Bianchi C
Cancer Detect Prev; 2000; 24(1):86-90. PubMed ID: 10757127
[TBL] [Abstract][Full Text] [Related]
9. Effects of cigarette smoking on serum fluoride concentrations and renal function integrity after 1 MAC-h sevoflurane anaesthesia.
Laisalmi M; Kokki H; Soikkeli A; Markkanen H; Yli-Hankala A; Rosenberg P; Lindgren L
Acta Anaesthesiol Scand; 2006 Sep; 50(8):982-7. PubMed ID: 16923094
[TBL] [Abstract][Full Text] [Related]
10. Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine.
Donadio C; Lucchesi A; Ardini M; Giordani R
J Pharm Biomed Anal; 2001 Mar; 24(5-6):835-42. PubMed ID: 11248475
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients.
Lukkonen A; Lintula S; von Boguslawski K; Carpén O; Ljungberg B; Landberg G; Stenman UH
Int J Cancer; 1999 Nov; 83(4):486-90. PubMed ID: 10508484
[TBL] [Abstract][Full Text] [Related]
12. Fluoride metabolism in smokers and non-smokers following enflurane anaesthesia.
Laisalmi M; Soikkeli A; Kokki H; Markkanen H; Yli-Hankala A; Rosenberg P; Lindgren L
Br J Anaesth; 2003 Dec; 91(6):800-4. PubMed ID: 14633748
[TBL] [Abstract][Full Text] [Related]
13. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
14. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
[TBL] [Abstract][Full Text] [Related]
15. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
16. Human alpha 1-microglobulin and its relationship to renal function.
Kusano E; Suzuki M; Asano Y; Itoh Y; Takagi K; Kawai T
Nephron; 1985; 41(4):320-4. PubMed ID: 2415841
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Rispoli G; Prontera C; Bianchi R; Fioretti P
Scand J Clin Lab Invest Suppl; 1991; 207():19-24. PubMed ID: 1780685
[TBL] [Abstract][Full Text] [Related]
18. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
19. Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.
Venesmaa P; Lehtovirta P; Stenman UH; Leminen A; Forss M; Ylikorkala O
Br J Cancer; 1994 Dec; 70(6):1188-90. PubMed ID: 7981075
[TBL] [Abstract][Full Text] [Related]
20. Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients.
Gaber A; Stene C; Hotakainen K; Nodin B; Palmquist I; Bjartell A; Stenman UH; Jeppsson B; Johnson LB; Jirström K
Radiat Oncol; 2011 Aug; 6():100. PubMed ID: 21864386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
